INTRODUCTION
Isolated lower extremity fractures are very common. 1, 2 These injuries are known to be risk factors for venous thromboembolism (VTE). [3] [4] [5] [6] Although studies using venographic outcomes suggest a 10%-40% incidence of deep vein thrombosis (DVT) after these fractures, most of these thrombi are distal, localized, and asymptomatic, and their clinical relevance is unknown. 5, [7] [8] [9] [10] [11] Some prophylaxis trials suggest that low-molecular weight heparin (LMWH) can reduce the incidence of asymptomatic DVT in patients with lower extremity injuries, although this finding was not specifically demonstrated in patients with fractures. 5, [7] [8] [9] [10] [11] Furthermore, the effectiveness of any method of thromboprophylaxis in decreasing the incidence of clinically important venous thromboembolism (CIVTE) in patients with isolated leg fractures is unknown, and there is uncertainty about the need for thromboprophylaxis resulting in significant practice variation. thromboprophylaxis seems to be common. [16] [17] [18] While the American College of Chest Physicians guidelines on the prevention of VTE recommend against the routine use of thromboprophylaxis in these patients, 12 the recent UK guidelines recommend that prophylaxis be used routinely in this setting. 19 The principal objective of this multicenter, randomized trial was to assess the effectiveness and safety of LMWH compared with placebo (usual care in North America) for the prevention of CIVTE in patients with isolated fractures distal to the knee that were managed surgically.
METHODS Patients
Consecutive patients aged at least 16 years admitted to 1 of 13 Canadian hospitals (see Appendix 1 for participating centers, Supplemental Digital Content 1, http://links.lww. com/BOT/A379) between August 2002 and October 2006 with unilateral or bilateral, closed or open fractures of the tibia, fibula, or ankle requiring surgical repair on the current admission were identified and assessed for eligibility. Patients who had concomitant patella or foot fractures, or soft tissue, ligament, or cartilage injuries were not excluded. However, patients with prespecified major trauma (see Appendix 2, Supplemental Digital Content 2, http://links.lww.com/BOT/A380) were excluded. Exclusion criteria are listed in Table 1 . The study protocol was approved by the research ethics boards at each hospital with written informed consent obtained before study participation. Three important protocol amendments to the eligibility criteria were proposed by the steering committee and approved by the hospitals' research ethics boards early after study commencement. The protocol initially excluded patients in whom surgery was delayed for more than 48 hours after injury. Since many patients did have their leg fracture surgery postponed beyond that time due to legitimate scheduling conflicts with more severe traumas at major trauma centers, this exclusion criterion was modified such that patients could be randomized preoperatively and start study medication as long as their surgery was done on that admission. To safeguard against patients who presented late to hospital after their injury, a 60-hour window between injury and presentation to hospital was suggested; this was subsequently increased to 72 hours as a second amendment to protocol. The third amendment expanded the eligibility criteria to include isolated fibular fractures as long as they were surgically repaired. These were originally excluded on the belief that they were relatively uncommon injuries but as the trial proceeded were found not to be so.
Study Design and Interventions
Eligible consenting patients were randomized to dalteparin 5000 anti-Xa units or matching placebo using a computerized randomization code with variable block sizes with stratification for study center developed by the statisticians at the Department of Research Design and Biostatistics at Sunnybrook Health Sciences Centre. Serially numbered kits with 16 prefilled syringes of study medication (dalteparin or matching placebo) per kit were prepackaged by the study sponsor according to the randomization sequence and distributed directly to study sites at the instruction of the coordinating site (Sunnybrook Health Sciences Centre). Patients and all research personnel were blinded to the study medication, which was administered subcutaneously once daily for 14 6 2 days, starting as soon as possible after randomization, but always within 72 hours of the fracture. If surgery was delayed, study medication was started preoperatively and restarted at the first regular dosing time after surgery. Other anticoagulants and mechanical thromboprophylaxis (compression stockings, pneumatic compression devices) were not allowed. Aspirin and other antiplatelet agents were allowed if they had been used before the injury for cardiac or stroke prophylaxis. Nonsteroidal antiinflammatory agents were allowed.
Patient Assessment and Follow-up
At baseline, each patient had a history and physical examination, complete blood count, International Normalized Ratio, activated Partial Thromboplastin Time, and serum creatinine. Patients were assessed daily while in hospital to ensure protocol adherence and monitor for symptoms and signs of possible VTE and adverse events. Patients discharged before 14 days were taught to self-inject their study medications and were telephoned every 2-3 days while receiving it. All patients were seen on day 14 6 2, compliance was assessed by syringe counts, complete blood count was repeated, and screening for proximal DVT was done with a bilateral Doppler ultrasound (DUS) using a standardized technique and reporting form, by certified vascular technologists with confirmation by staff radiologists, both blinded to treatment assignment. Plaster casts were removed for this examination if needed. Proximal deep veins were imaged from the common femoral vein down to the trifurcation of the calf veins with the primary diagnostic criterion for DVT Patients with a normal DUS examination discontinued study medication and were not given any subsequent thromboprophylaxis. All patients were interviewed by telephone at 6 weeks 6 1 week and 3 months 6 1 week to assess their clinical status and to inquire about unscheduled hospital or physician visits, symptoms of possible VTE, cointervention, bleeding, and other adverse events. Clinical suspicion of DVT or pulmonary embolism (PE) during the 3-month study period was investigated using objective diagnostic tests and prespecified diagnostic algorithms (see Appendix 3 and 4, Supplemental Digital Content 3 and 4, http://links.lww.com/BOT/A381).
All patients who developed objectively confirmed DVT or PE (symptomatic or asymptomatic) were treated with full-dose anticoagulant therapy (generally LMWH followed by warfarin) for approximately 3 months.
Outcome Measures
The primary outcome in the D-KAF Study was CIVTE, a composite of symptomatic proven DVT or PE (including fatal PE) within the 3-month study period and asymptomatic proximal DVT at the end of the prophylaxis phase. Symptomatic PE was defined as clinically suspected PE confirmed by positive spiral computed tomography pulmonary angiogram, high probability V/Q lung scan, or leg imaging. Fatal PE was defined as autopsy-proven PE; possible fatal PE was defined as otherwise unexplained, sudden death in patients without an autopsy. Secondary effectiveness outcomes were CIVTE during the prophylaxis phase (from randomization to discontinuation of study medication) and symptomatic VTE during the postprophylaxis follow-up period (from discontinuation of study medication to 3 months). The primary safety outcome was major bleeding occurring between the first dose of study drug and 2 days after the last dose. Major bleeding was defined as overt bleeding that was fatal, life-threatening or involved a critical organ or a major joint, required surgical intervention, the transfusion of 1 or more units of red blood cells within 48 hours of the bleeding event, or was associated with a drop in hemoglobin of at least 20 g/L within 48 hours of the bleeding event. Minor bleeding was overt bleeding that did not meet the criteria for major bleeding. Other safety outcomes were heparin-induced thrombocytopenia (HIT), serious adverse events (SAEs), and death. An independent outcomes adjudication committee with access to pertinent clinical data and diagnostic test results but blinded to treatment assignments evaluated all cases with suspected VTE using prespecified adjudication criteria. Similarly, an independent, blinded, safety committee adjudicated all bleeding and SAEs.
Statistical Analysis and Early Stopping
The baseline characteristics of the 2 study groups were compared using t tests for continuous variables and x 2 tests for proportions. The primary analysis for effectiveness was based on an intention-to-treat population, which consisted of all randomized patients who met the inclusion criteria, received at least 1 dose of study medication, and had a DUS at the end of the prophylaxis period or had objectively confirmed symptomatic VTE during the study period. The difference in rates of CIVTE between the dalteparin and placebo groups was assessed using a 1-tailed Fisher exact test and 95% confidence intervals. A 1-tailed test was selected since it was felt to be biologically implausible for the control group to have significantly fewer thromboembolic outcomes than the prophylaxis group. All randomized patients who received at least 1 dose of study medication were included in the safety analyses.
It was estimated that asymptomatic DVT (detected by proximal DUS) would occur in 4%-5% of patients who received placebo 7, 8 and symptomatic VTE in 1%-2%.
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The expected rate of CIVTE in the placebo arm was, therefore, estimated to be 4%-6%. Since the relative risk reductions in studies of LMWH versus controls range from 60% to 80%, 24 we expected that LMWH would reduce the primary outcome of CIVTE from 4% in the control arm to 1%, a clinically important difference (number needed to prophylax = 33). Assuming an a = 0.05 (1-tailed) and a 5% withdrawal rate after randomization, this study would have 80% power to detect a 75% risk reduction with a planned sample size of 350 patients per group. Because the event rates were not precisely defined for this population, a formal, blinded interim analysis was planned after outcomes were available for the first 500 patients. After 245 patients completed their follow-up, the overall event rate in both groups was 1.9% as compared with an estimated 2.5% according to the planned sample size estimates. The steering committee, therefore, requested an early interim analysis, the results of which suggested that, given the observed CIVTE rate at that point in the trial, we would not be able to show a difference between groups even with doubling the original sample size. Based on this analysis, the steering committee made the decision to stop recruitment without unblinding.
Two of the investigators (R.S. and W.H.G.) developed the initial protocol that was revised and approved by the 6 members of the steering committee. The steering committee supervised the trial, made the decision to stop the trial, reviewed the results, and prepared the article. The outcomes adjudication committee and the safety committee were independent of the steering committee. Neither the Canadian Institutes of Health Research nor Pfizer Canada were involved in any aspect of protocol development, conduct of the trial, or the decision to publish.
RESULTS
During the study period, 1926 patients were consecutively screened (Fig. 1 ) and 1661 were excluded based on criteria described in Table 1 . Of the 265 enrolled patients, 134 were randomized to receive dalteparin and 131 to placebo with no significant differences between the 2 groups ( Table 2) .
Venous Thromboembolism
Of the 265 randomized patients, 258 (97%) were included in the primary outcome analysis for effectiveness, 130 on dalteparin, and 128 on placebo (Fig. 1) . Of the 7 patients who were excluded, 2 patients (1 per group) withdrew consent after randomization, at day 1 and day 3. One patient on dalteparin did not return for day 14 follow-up and could not be contacted. Another, also on dalteparin, had to be withdrawn from the study due to postoperative shortness of breath requiring intensive care unit (ICU) transfer, for which PE was ruled out. Three patients (2 randomized to placebo and 1 to dalteparin) were found not to have met the inclusion criteria after randomization as they did not have tibial or ankle fractures. The 2 patients receiving placebo had a talus and a calcaneal fracture, respectively, and the patient receiving dalteparin had a patellar fracture.
Overall, only 5 patients developed CIVTE (1.9%, 95% confidence interval: 0.7 to 4.7), 2 in the dalteparin group and 3 in the placebo group (1.5% vs. 2.3%, P = 0.68) ( Table 3) . Two of these events were asymptomatic proximal DVT detected on day 14 DUS, 1 each in the placebo and dalteparin groups. Two were symptomatic proximal DVT, 1 each in the placebo and dalteparin groups, documented by proximal DUS on day 11 and day 17, respectively. One symptomatic nonfatal PE in the placebo group occurred on day 11 before the scheduled DUS. Three patients had calf vein thrombi detected by whole-leg DUS, performed as protocol violations. The adjudication committee decided to exclude these events from the analysis as they were not predefined components of the primary outcome and would not have been detected if the protocol for proximalonly DUS had been adhered to. Two of these were in the dalteparin and 1 in the placebo group. Two of these calf DVTs were treated. Of the 4 proximal DVTs included in the analysis, 3 were ipsilateral to the fractured leg and 1 was bilateral. Of the 3 calf DVTs excluded from the analysis, 2 were ipsilateral and 1 contralateral to the side of the fracture. The overall event rates were too low to allow multivariate analyses for predictors of VTE.
Safety Events
There were no major bleeds or episodes of suspected or proven HIT in either group (Table 3 ). There were 3 minor bleeds (2 in the dalteparin arm). Two were nose bleeds and 1 was increased bruising in the operated leg. There were 4 SAEs, 2 in each group, none of which were related to the study medication. A 67-year-old woman with a closed left tibial plateau fracture and no other major injuries developed progressive shortness of breath on the day after surgery. PE was suspected but ruled out. Imaging revealed adult respiratory distress syndrome, which required intubation and transfer to the ICU. A decision was made to discontinue study medication and thromboprophylaxis with LMWH was started. In the ICU, she developed progressive multiorgan failure and expired approximately 3 weeks later. Two patients with closed tibial plateau fractures had postoperative wound infections that required extension of their hospital stay. One patient with a closed malleolus fracture fell and refractured her ankle requiring additional surgery and resulting in prolongation of hospitalization.
Compliance With Study Medication
Two hundred forty-two patients (91%) received all 14 doses of study medication. Twenty-three patients received fewer than 14 doses of study medication, 13 in the dalteparin group and 10 in the placebo group.
DISCUSSION
Our study showed that among patients with surgically repaired tibia and ankle fractures, the combined rate of symptomatic VTE and asymptomatic proximal DVT was not lowered by dalteparin in a standard prophylaxis dose of 5000 units once daily for 14 days compared with placebo but that this prophylaxis regimen was safe, with no increase in bleeding or HIT.
To date, 6 other randomized controlled trials have been published addressing the efficacy of LMWH thromboprophylaxis in patients with isolated lower extremity injuries.
5,7-11 Our study cannot be directly compared with any of these trials because of important differences in study populations and outcome ascertainment. Four of the 6 previous studies included patients with lower limb injuries other than fractures, including soft tissue injuries or Achilles tendon repairs, whereas our study and the trials by Lapidus et al 11 and Goel et al 5 included only patients with surgically treated tibia and ankle fractures. The active treatment arms in these trials used various prophylactic doses of 5 different LMWHs for average periods ranging from 14 days up to 44 days. The primary efficacy outcomes in 4 of the studies were based on routine contrast venography, whereas the remaining 2 were based on an ultrasound technique as in our trial. In each of the other trials, asymptomatic calf DVT was the main contributor to the primary outcome, whereas our trial focused on clinically important VTE. In the control groups of the venography studies, the DVT rates ranged from 6% to 31%. Prophylaxis with LMWH was not shown to reduce asymptomatic DVT among fracture patients in 5 of these studies. Only one of the older ultrasound-based studies showed that LMWH significantly reduced DVT compared with placebo, and this trial included only 77 patients. 7 In addition, these 2 earlier trials have major limitations that reduce their utility, including the small proportion of patients with fractures (30% and 21%), outpatient, nonoperative management in all cases, unblinded design, lack of disclosure of the method of randomization, high rates of postrandomization dropouts (17% and 31%), incomplete reporting of outcomes in fracture patients, and marked variation in study duration (1-72 days). 7, 8, 25, 26 Comparing the frequency of asymptomatic venographically screened DVT found in the no prophylaxis groups of 4 of these studies (19%) with the very low rate of clinically important VTE found in our study (2%) highlights the significant discrepancy between prophylactic trials using venographic end points versus those using outcomes that are more clinically relevant. Although asymptomatic venographically documented DVT (mostly calf vein thrombosis) clearly do occur after lower extremity injuries, 3,5,9-11 the rate of conversion to clinically important VTE seems to be low. Although the single proximal DUS in our trial did not detect most of the asymptomatic calf DVT that must have been present, only one of the 252 patients had proven VTE in the 10-week postprophylaxis phase despite being immobile for more than 40 days. In a prospective study of 201 patients who underwent surgery of the foot and ankle, calf DVT was detected by DUS in 7 (3.5%), none of whom had progression on follow-up ultrasound in the absence of any treatment. 27 Another study detected asymptomatic DVT in 5 of 100 patients with ankle fractures and also found no progression of the thrombosis in the absence of treatment. 13 Among the 1310 below-knee fracture patients in the 7 randomized trials, there were no fatal pulmonary emboli during the prophylaxis periods or on follow-up. These studies, therefore, suggest that venography detects a large number of clinically irrelevant thrombi. Among patients who have undergone ankle fracture surgery, the sensitivity and specificity of DUS for proximal DVT has been shown to be 100%. 28 In thromboprophylaxis trials, the dependence on mandatory contrast venography is appropriately in evolution. We believe that new interventions with unknown efficacy should first be assessed using highly sensitive screening methods such as contrast venography or validated whole-leg DUS. However, when assessing the clinical relevance of 1 or more approaches to thromboprophylaxis that have already demonstrated efficacy, we suggest that larger trials use CIVTE as the primary effectiveness outcome rather than depending on asymptomatic, predominantly calf, DVT.
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Although meta-analyses of randomized trials in patients with various below-knee injuries demonstrate a significant reduction in asymptomatic DVT with use of LMWH, 26,29 6 of the 7 individual studies, including ours, have not shown that LMWH prophylaxis is able to significantly reduce the frequency of either asymptomatic DVT or major VTE outcomes in this patient group. Given the low incidence of CIVTE, future trials may not be feasible and are unlikely to demonstrate a favorable benefit-to-risk ratio unless a high-risk group can be identified.
Our study has a number of strengths. It is the first double-blind, randomized clinical trial in patients with isolated below-knee fractures that used CIVTE as the primary outcome, it was multicenter and generalizable to both academic and community centers, included a spectrum of lower extremity fractures, had standardized investigation protocols with blinded outcome assessment to minimize bias, a high rate of compliance with injection therapy, and a very low loss to follow-up at 3 months. Our study also has some limitations. We were able to randomize only 14% of consecutive patients primarily due to a refusal rate of over 50% in eligible patients. Although we did not formally assess the reasons for refusal to participate, low acceptance of selfinjection of LMWH seemed to be the commonest reason. The sample size is relatively small, and we stopped the study early because of the low overall event rates. However, a blinded interim analysis demonstrated that we were very unlikely to demonstrate a significant difference by continuing the trial. Finally, the overall incidence of thromboembolic events in our study was too low to analyze for predictors of VTE in these patients.
Current evidence, including the results of this study, previous randomized trials, 5, [7] [8] [9] [10] [11] and a large cohort study in patients with lower extremity fractures who did not receive thromboprophylaxis, 30 demonstrates that clinically important thromboembolic event rates are low, that LMWH does not significantly reduce these events and that patient acceptance of self-injection under these circumstances is low. Therefore, routine thromboprophylaxis in patients with isolated, distal, lower extremity fractures cannot be recommended. Whether there are subgroups of patients with isolated, below-knee fractures who are at sufficient risk to warrant thromboprophylaxis, and if so, the type and duration of prophylaxis in such patients remains an unanswered question at this time and may be addressed by future studies.
